Gut microbiota as a multifaceted modulator of prostate cancer: Mechanistic insights, therapeutic opportunities and clinical challenges (Review).

Prostate cancer ranks among the most prevalent malignancies in men worldwide, necessitating innovative therapeutic strategies.

• The paper frames PCa's high prevalence as the primary motivation for investigating gut microbiota as a novel therapeutic target.
• The review emphasizes the need for personalized approaches to PCa management.
• The paper positions gut microbiota research as an 'emerging field' in PCa.

Gut microbiota influences prostate cancer pathogenesis through immunomodulation and metabolic regulation.

• The review systematically examined mechanisms by which gut microbiota affects PCa.
• Two primary mechanistic pathways identified were immunomodulation and metabolic regulation.
• The paper describes the gut microbiota as a 'multifaceted modulator' of PCa.

Microbial dysbiosis is clinically linked to prostate cancer risk.

• The review highlighted clinical evidence connecting microbial dysbiosis to PCa risk.
• The paper examined the composition and diversity of gut microbiota in relation to PCa.
• Discrepancies in existing research on the dysbiosis-PCa relationship were noted and examined.

Modulation of the gut microbiota through probiotics and dietary interventions shows therapeutic potential for enhancing PCa treatment responses.

• Probiotics were identified as one approach for microbiota modulation in PCa management.
• Dietary interventions were identified as a second major approach for microbiota modulation.
• The therapeutic goal described was 'enhancing treatment responses' rather than direct tumor elimination.

Significant challenges persist in gut microbiota research in prostate cancer, including methodological variations and patient heterogeneity.

• Methodological variations across studies were identified as a key challenge limiting conclusions.
• Patient heterogeneity was identified as an additional challenge complicating research findings.
• These challenges were described as persisting 'despite emerging insights' in the field.
• The paper called for further research to elucidate the role of the gut microbiota in PCa.

Gaps in existing research were identified and future directions proposed to advance understanding of gut microbiota's role in prostate cancer.

• The paper described its novelty as a 'comprehensive synthesis of current evidence on the role of the gut microbiota in PCa.'
• Identification of gaps in existing research was highlighted as a key contribution of the review.
• The review proposed future directions to advance understanding of this field.
• The paper emphasized the need for development of personalized approaches for PCa management.